Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...

For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

Researchers at the University of Copenhagen have developed a new weight-loss drug that may surpass the effectiveness of ...

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...